Learning objectives: Identify risk factors for the development of second malignant neoplasms.

Identify the multiple molecular pathways leading to t-MN, and implications for the treatment of both the primary malignant disease and the subsequent myeloid neoplasm.

Session date: 
09/04/2018 - 12:00pm to 1:00pm CDT
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Michelle M. Le Beau, PhD